Repros Therapeutics Inc. (RPRX) Sees Significant Increase in Short Interest
Repros Therapeutics Inc. (NASDAQ:RPRX) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling 1,052,988 shares, an increase of 46.2% from the August 31st total of 720,417 shares. Currently, 4.4% of the company’s stock are short sold. Based on an average trading volume of 616,009 shares, the days-to-cover ratio is currently 1.7 days.
Shares of Repros Therapeutics (NASDAQ:RPRX) opened at 2.07 on Wednesday. The company’s market capitalization is $50.34 million. Repros Therapeutics has a 12 month low of $0.80 and a 12 month high of $8.12. The stock has a 50 day moving average price of $2.07 and a 200-day moving average price of $1.89.
Repros Therapeutics (NASDAQ:RPRX) last announced its quarterly earnings results on Tuesday, August 9th. The company reported ($0.18) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.20) by $0.02. Repros Therapeutics had a negative net margin of 53,658.53% and a negative return on equity of 130.80%. Analysts forecast that Repros Therapeutics will post ($0.70) EPS for the current year.
Several analysts have weighed in on RPRX shares. S&P Equity Research lifted their price objective on Repros Therapeutics from $2.12 to $2.47 in a research report on Thursday, September 8th. Zacks Investment Research raised Repros Therapeutics from a “hold” rating to a “buy” rating and set a $2.50 price objective on the stock in a research report on Tuesday, August 16th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and one has given a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and a consensus target price of $2.32.
Several hedge funds and other institutional investors have recently made changes to their positions in RPRX. Geode Capital Management LLC increased its position in shares of Repros Therapeutics by 14.8% in the first quarter. Geode Capital Management LLC now owns 147,473 shares of the company’s stock worth $143,000 after buying an additional 18,990 shares during the last quarter. Renaissance Technologies LLC raised its stake in Repros Therapeutics by 424.0% in the first quarter. Renaissance Technologies LLC now owns 177,713 shares of the company’s stock worth $172,000 after buying an additional 143,800 shares during the period. Allegis Investment Advisors LLC raised its stake in Repros Therapeutics by 0.3% in the second quarter. Allegis Investment Advisors LLC now owns 342,709 shares of the company’s stock worth $569,000 after buying an additional 1,040 shares during the period. BlackRock Institutional Trust Company N.A. raised its stake in Repros Therapeutics by 24.6% in the second quarter. BlackRock Institutional Trust Company N.A. now owns 674,848 shares of the company’s stock worth $1,087,000 after buying an additional 133,237 shares during the period. Finally, Vanguard Group Inc. raised its stake in Repros Therapeutics by 21.1% in the second quarter. Vanguard Group Inc. now owns 1,004,041 shares of the company’s stock worth $1,617,000 after buying an additional 174,610 shares during the period. 24.14% of the stock is owned by hedge funds and other institutional investors.
About Repros Therapeutics
Repros Therapeutics, Inc is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company’s product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis.
Receive News & Stock Ratings for Repros Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repros Therapeutics Inc. and related stocks with our FREE daily email newsletter.